XSTO
CLBIO
Market cap35mUSD
Jul 11, Last price
13.70SEK
1D
-0.36%
1Q
58.56%
Jan 2017
35.64%
IPO
41.28%
Name
Corline Biomedical AB
Chart & Performance
Profile
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; CHC, which is used for the treatment of soft tissue injuries; medical devices; and CHS, a coronary stent. The company was founded in 1991 and is based in Uppsala, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 9,775 -60.95% | 25,030 6.28% | 23,550 233.47% | |||||||
Cost of revenue | (3,666) | (3,350) | 824 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 13,441 | 28,380 | 22,726 | |||||||
NOPBT Margin | 137.50% | 113.38% | 96.50% | |||||||
Operating Taxes | 549 | |||||||||
Tax Rate | 2.42% | |||||||||
NOPAT | 13,441 | 28,380 | 22,177 | |||||||
Net income | (23,194) 1,182.14% | (1,809) -177.67% | 2,329 -133.68% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 16,792 | 537 | 26 | |||||||
BB yield | -8.77% | -0.17% | -0.01% | |||||||
Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 4,341 | |||||||||
Net debt | (17,668) | (17,013) | (26,211) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (8,639) | 886 | (6,452) | |||||||
CAPEX | (7,497) | (132) | (8,999) | |||||||
Cash from investing activities | (7,497) | (10,621) | (8,999) | |||||||
Cash from financing activities | 16,792 | 537 | 26 | |||||||
FCF | 13,536 | 39,070 | 11,355 | |||||||
Balance | ||||||||||
Cash | 17,668 | 17,012 | 26,210 | |||||||
Long term investments | 1,000 | 1,000 | ||||||||
Excess cash | 17,179 | 15,762 | 25,034 | |||||||
Stockholders' equity | (145,056) | (61,877) | 5,015 | |||||||
Invested Capital | 231,970 | 155,193 | 89,574 | |||||||
ROIC | 6.94% | 23.19% | 31.17% | |||||||
ROCE | 15.46% | 30.41% | 24.03% | |||||||
EV | ||||||||||
Common stock shares outstanding | 21,811 | 21,677 | 21,491 | |||||||
Price | 8.78 -41.07% | 14.90 61.61% | 9.22 -36.85% | |||||||
Market cap | 191,504 -40.71% | 322,992 63.01% | 198,145 -33.60% | |||||||
EV | 173,836 | 305,979 | 235,224 | |||||||
EBITDA | 13,536 | 28,477 | 22,782 | |||||||
EV/EBITDA | 12.84 | 10.74 | 10.33 | |||||||
Interest | 32 | 26 | ||||||||
Interest/NOPBT | 0.24% | 0.09% |